IQV241220C320000
- 0.75
- 0.000.00%
IQVIA Holdings Newsroom
IQVIA Hldgs Analyst Ratings
Nephron Upgrades IQVIA Holdings(IQV.US) to Buy Rating, Announces Target Price $250
Nephron Research Upgrades IQVIA to Buy, Price Target Is $250
Baird Maintains IQVIA Holdings(IQV.US) With Hold Rating, Cuts Target Price to $213
Redburn Atlantic Adjusts Price Target on IQVIA Holdings to $255 From $276, Maintains Buy Rating
Deutsche Bank Maintains IQVIA Holdings(IQV.US) With Buy Rating, Maintains Target Price $265
IQVIA Hldgs Analyst Ratings
Leerink Adjusts Price Target on IQVIA Holdings to $248 From $260, Maintains Outperform Rating
Mizuho Securities Maintains IQVIA Holdings(IQV.US) With Buy Rating, Announces Target Price $247
Argus Research Maintains IQVIA Holdings(IQV.US) With Buy Rating, Announces Target Price $260
RBC Capital Maintains IQVIA Holdings(IQV.US) With Buy Rating, Maintains Target Price $270
IQVIA Holdings Price Target Cut to $240.00/Share From $279.00 by JP Morgan
IQVIA Holdings Is Maintained at Overweight by JP Morgan
RBC Capital Reiterates Outperform on IQVIA Hldgs, Maintains $270 Price Target
A Quick Look at Today's Ratings for IQVIA Holdings(IQV.US), With a Forecast Between $240 to $273
Analysts Offer Insights on Healthcare Companies: Glaukos (GKOS), Regeneron (REGN) and IQVIA Holdings (IQV)
Analysts Conflicted on These Healthcare Names: IQVIA Holdings (IQV), Halozyme (HALO) and Kymera Therapeutics (KYMR)
Stifel Nicolaus Reaffirms Their Buy Rating on IQVIA Holdings (IQV)
IQVIA Holdings Price Target Cut to $265.00/Share From $286.00 by Truist Securities
IQVIA Hldgs Analyst Ratings